

DERMATOLOGY ORDER SET

DERMATOLOGY ORDERS:				
Patient Name:Email:	DOB:	Phone:		
Liliali.				
\Box New to therapy $\ \Box$ Continuing therapy: next treatment date:		·		
MEDICAL INFORMATION:				
☐ L50.1 - Chronic Idiopathic Urticaria				
\square M33.10 – Dermatomyositis \square M33.90 - Dermatopolymyosi	itis			
☐ L10.0 – Pemphigus vulgaris				
\square L40.50 - Psoriasis, arthropathic \square L40.0 - Psoriasis, plaque				
□ Other				
THERAPY ORDERS:				
□ *Cimzia: Dose: □ 200mg subcutaneously every 2 weeks □ 400 □ 400mg subcutaneously at weeks 0, 2, and 4 for	_			
☐ Ilumya: Initial Dose: ☐ 100mg subcutaneously at weeks 0, 4,	and every 12 w	eeks thereafter		
Maintenance Dose: □ 100mg subcutaneously every 13	2 weeks Refil	ls: 1yr Other:		
□ *Infliximab: Dose:mg/kg Frequency: □ Everyv Refills: □ 1yr □ Other:	weeks OR 🗆 0, 2	2, 6, then every 8 weeks		
□ *IVIG: Dose: □mg/kg OR □gm/kg IV xday Frequency: □ Every weeks OR Other				
☐ Xolair : Dose: ☐ 150mg ☐ 300mg subcutaneously every 4 wee	eks Refills: 🛭] 1yr □ Other:		
□ *Rituximab: Initial dose: □ 1000mg IV at day 0 and 15 Maintenance dose: □ 500mg IV at month 12 and 6	every 6 months	thereafter Refills:		
□ *Simponi Aria: □ Initial Dose: 2mg/kg at weeks 0,4, and then □ Maintenance Dose: 2mg/kg every 8 weeks	-	□ Other:		
□ *Stelara: Initial Dose: □ 45mg subcutaneously initially, 4 weeks □ 90mg subcutaneously initially, 4 weeks Maintenance Dose: □ 45mg □ 90mg subcutaneously	later, followed	by 90mg every 12 weeks		

*See opposite page for required pre-screening

PLEASE COMPLETE BOTH SIDES OF THIS FORM



DERMATOLOGY ORDER SET

DERMATOLOGY ORDERS:				
Patient Name:		DOB:	Phone:	
PREMEDICATION ORD	DERS:			
☐ Tylenol: ☐ 500mg ☐ Antihistamine (cho	oose one): Cetirizine 2	10mg by mouth □ Diphenhydra e 10mg by mouth	amine 25mg by mouth	
☐ Solu-Medrol ☐ Other:	_			
		CES, OR CONTRAINDICATIONS mide, methotrexate, mycophe	TO CONVENTIONAL THERAPY (e.g., enolate):	
_				
REQUIRED PRE-SCREE	NING:			
Required for: Cimzia, I Hepatitis B screenii Required for: Cimzia, I Hepatitis B core an Serum immunoglo Baseline creatinine	llumya, Infliximab, Simp ng (surface antigen) w/ Infliximab, Rituximab, c tibody total (not IgM) v bulins w/attached resu w/attached results Re	attached □ *Positive □ Negative	<u></u>	
REQUIRED ASSOCIAT	ED DOCUMENTATION:			
☐ Include clinical note ☐ Include clinical note ☐ If applicable - Last	es supporting the aboves supporting contraing know biological therap	re diagnoses. dication/intolerance, or failed t y: and last date re	edication list Labs and/or test results rial of conventional therapy or biologic. ceived: weeks prior to starting ordered biologic.	
REFERRING PROVIDE	R INFORMATION:			
Provider name:		Signature:	Date:	
NIDI	DI	F .		

FAX COMPLETED FORM TO US INFUSIONS AT 469-200-2606